Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK1358820 in Post-stroke Upper Limb Spasticity
NCT03261167Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2017
- Primary completion
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in Upper limb spasticity (2 arms), sponsored by GSK. Primary endpoint: Percentage of Participants Who Had Modified Ashworth Scale (MAS) Score Reduced at Least 1 From Baseline in the Elbow Flexors at Week 6. Started Aug 2017; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
Upper limb spasticity
Beyond the preview
Go deeper on NCT03261167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03261167.